Kamada Ltd. (KMDA)
| Previous close | 5.22 |
| Open | 5.26 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.26 - 5.37 |
| 52-week range | 4.08 - 6.53 |
| Volume | |
| Avg. volume | 21,059 |
| Market cap | 310.889M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 35.80 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024. Kamada management will host an
- GlobeNewswire
Kamada Issues 2024 CEO Letter to Shareholders
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2023 was another successful period in our com
- GlobeNewswire
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over-YearStrong Momentum Supports Expected Double-Digit Growth with Anticipated Fiscal Year 2024 Revenues in Range of $156 to $160 Million and Expected Adjusted EBITDA in Range of $27 to $30 MillionKamada Maintains Financial Strength to Accelerate Growth and Pursue Compelling New Business Developm
